Alnylam Pharmaceuticals Affirms FY2026 Sales Guidance of $5.275B-$5.725B vs $5.471B Est
Benzinga Newsdesk 1 day ago
NewsGuidance
Alnylam Pharmaceuticals (NASDAQ:ALNY) affirms FY2026 sales outlook from $5.275 billion-$5.725 billion to $5.275 billion-$5.725 billion vs $5.471 billion estimate.
Alnylam Pharmaceuticals (NASDAQ:ALNY) affirms FY2026 sales outlook from $5.275 billion-$5.725 billion to $5.275 billion-$5.725 billion vs $5.471 billion estimate.